Synthetic Biologics Overview

  • Founded
  • 1986
Founded
  • Status
  • Public
  • Employees
  • 11
Employees
  • Stock Symbol
  • SYN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.71
  • (As of Thursday Closing)

Synthetic Biologics General Information

Description

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Therapeutic Devices
Other Industries
Medical Supplies
Biotechnology
Stock Exchange
ASE
Primary Office
  • 9605 Medical Center Drive
  • Suite 270
  • Rockville, MD 20850
  • United States
+1 (301) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Synthetic Biologics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.71 $0.54 $0.25 - $0.75 $13M 19.4M 588K -$0.93

Synthetic Biologics Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 13,732 5,111 8,288 54,378
Revenue 0 0 0 0
EBITDA (14,135) (15,423) (13,216) (15,268)
Net Income (14,091) (15,303) (13,367) (15,174)
Total Assets 9,582 17,235 30,141 18,838
Total Debt 602 722 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Synthetic Biologics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synthetic Biologics‘s full profile, request access.

Request a free trial

Synthetic Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfol
Therapeutic Devices
Rockville, MD
11 As of 2020
000.00
000000000 000.00

000000 0

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conseq
00000000000 0000000
Rehovot, Israel
00 As of 0000
000.00
000000000 000.00

00000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
0000 000000000
Ness Ziona, Israel
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synthetic Biologics Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Beyond Air Formerly VC-backed Rehovot, Israel 00 000.00 000000000 000.00
00000 Formerly VC-backed Ness Ziona, Israel 00 00000 00000000000 00000
00000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
0000000 0000000000 Venture Capital-Backed Boston, MA 000.00 00000000000 000.00
00000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
You’re viewing 5 of 14 competitors. Get the full list »

Synthetic Biologics Executive Team (10)

Name Title Board Seat Contact Info
Steven Shallcross Chief Executive Officer & Chief Financial Officer, Finance
Vincent Perrone Director, Corporate Communications
Vince Wacher Ph.D Head of Corporate & Product Development
Sheila Connelly Ph.D Vice President of Research
John Monahan Ph.D Advisor, Research & Development
You’re viewing 5 of 10 executive team members. Get the full list »

Synthetic Biologics Board Members (3)

Name Representing Role Since
0000000 00000 Self Chairman 000 0000
0000000 0000 00 Self Board Member 000 0000
00000 0000000 Self Board Member 000 0000
To view Synthetic Biologics’s complete board members history, request access »

Synthetic Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synthetic Biologics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Synthetic Biologics‘s full profile, request access.

Request a free trial

Synthetic Biologics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 000 (00000000 28-Nov-2012 000000000 00000 00 000.00 Buildings and Property 0000000 00000
To view Synthetic Biologics’s complete investments history, request access »